Hangzhou Alltest Biotech Co., Ltd.

Shanghai Stock Exchange 688606.SS

Hangzhou Alltest Biotech Co., Ltd. Gross Profit Margin for the year ending December 31, 2023: 48.78%

Hangzhou Alltest Biotech Co., Ltd. Gross Profit Margin is 48.78% for the year ending December 31, 2023, a -18.61% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Hangzhou Alltest Biotech Co., Ltd. Gross Profit Margin for the year ending December 31, 2022 was 59.93%, a 8.64% change year over year.
Hangzhou Alltest Biotech Co., Ltd. Gross Profit Margin for the year ending December 31, 2021 was 55.17%, a -32.93% change year over year.
Hangzhou Alltest Biotech Co., Ltd. Gross Profit Margin for the year ending December 31, 2020 was 82.25%, a 32.05% change year over year.
Hangzhou Alltest Biotech Co., Ltd. Gross Profit Margin for the year ending December 31, 2019 was 62.29%, a -0.97% change year over year.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

Shanghai Stock Exchange: 688606.SS

Hangzhou Alltest Biotech Co., Ltd.

CEO	Mr. Fei Gao
IPO Date	March 25, 2021
Location	China
Headquarters	#550, Yinhai Street
Employees	1,093
Sector	Health Care
Industries Biotechnology Chemicals & Advanced Materials Pharmaceuticals

Description

Hangzhou Alltest Biotech Co., Ltd. engages in the research, development, production, and market of in vitro diagnostic reagents worldwide. It offers rapid diagnostic products, including women's health, infectious diseases, drugs, cancer, cardiovascular, and other five series of products. The company is based in Hangzhou, China.

Key trends

Past 5 years